DexCom
NASDAQ: DXCMSan Diego, US · Delaware corporation · 9,000 employees on LinkedIn · 1 known investors
Dexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.
Founders & leadership
RD
Richard DoubledayExecutive
SR
Steven R. PacelliinEVP & Managing Director, Dexcom Ventures2020–2025
JM
Jeffrey MoyExecutive
TH
Terrance H. GreggExecutive
JV
Jorge ValdesinChief Technology Officer2005–2017
JD
John D. ListerinGeneral Manager, EMEA2015–2019
JR
AK
Andrew K. BaloExecutive
Board
ET
Eric TopolBoard director
BE
Barbara E. KahnBoard director
JT
Jonathan T. LordBoard director
NA
Nicholas AugustinosBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.2M disclosed across 1 round · 2016
▶$7.2MraisedMay 2016 · 2 investors · BiotechnologyRule 506(b)
▶$7.2MraisedMay 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard DoubledayExecutive Officer
- Eric TopolDirector
- Barbara E. KahnDirector
- Steven R. PacelliExecutive Officer
- Jonathan T. LordDirector
- Jeffrey MoyExecutive Officer
- Nicholas AugustinosDirector
- Terrance H. GreggExecutive Officer, Director
- Jorge ValdesExecutive Officer
- John D. ListerExecutive Officer
- Jess RoperExecutive Officer
- Andrew K. BaloExecutive Officer
- Jay S. SkylerDirector
- Kevin SayerExecutive Officer, Director
- Steven R. AltmanDirector
- Mark FolettaDirector
- Offering amount
- $7.2M
- Amount sold
- $7.2M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Diabetes9706 shared keywordsA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
Nutrisense7021 shared keywordsNutrisense provides personalized metabolic monitoring and health guidance through continuous glucose monitoring and data analysis. The platform helps individuals understand their body's metabolic response to food and lifestyle choices to build sustainable health habits.
Lark5202 shared keywordsLark develops an AI-powered health coaching platform that delivers personalized support for chronic disease prevention and management through 24/7 text-based conversations and integration with smart health devices. The platform serves individuals seeking affordable, accessible care for chronic conditions.
Companies competing with DexCom for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Agofinance.yahoo.com · Aug 2026
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?finance.yahoo.com · Aug 2026
DexCom (DXCM) Stock Surges On Margin Strength And Raised Outlooksahmcapital.com · Aug 2026
DexCom gains as investors appear to welcome earnings momentum and growth outlook | Quiver Quantitativequiverquant.com · Jul 2026Frequently asked questions
- What does DexCom do?
- Dexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.
- Who are DexCom's investors?
- DexCom's investors include Canaan Partners.
- How much funding has DexCom raised?
- DexCom has disclosed $7.2M raised across 1 round.
- Where is DexCom headquartered?
- DexCom is headquartered in San Diego, US.